ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 368.3 | 302.8 | 357.4 |
| Other income | 7.8 | 5.4 | 4.9 |
| Total income | 376.1 | 308.2 | 362.3 |
| Profit before exceptional items & tax | 25.1 | -1.8 | 21.2 |
| Exceptional items | -0.2 | -7.1 | 0.0 |
| Profit before tax | 24.8 | -8.9 | 21.2 |
| Net profit | 25.8 | -9.3 | 34.0 |
| Operating margin | 6.6% | -2.9% | 5.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -24.10% |
|---|---|
| Revenue, year on year | +3.00% |
| Operating profit, year on year | +6.10% |
| Operating profit, quarter on quarter | +340.30% |
NSE results filing, NSE: ORCHPHARMA. Figures extracted from the filing.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.